Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	48.61
Equity-to-Asset	0.63
Debt-to-Equity	0.01
Debt-to-EBITDA	0.1
Interest Coverage	2.28
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.34	Distress Grey Safe
Beneish M-Score	-2.53	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	10.2
	3-Year Book Growth Rate	24.8
	Future 3-5Y EPS without NRI Growth Rate	61.58
	Future 3-5Y Total Revenue Growth Rate	11.51

Momentum Rank

10/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	23.4
	9-Day RSI	30.56
	14-Day RSI	37
	6-1 Month Momentum %	16.32
	12-1 Month Momentum %	18.39

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.87
	Quick Ratio	1.82
	Cash Ratio	1.18
	Days Inventory	88.32
	Days Sales Outstanding	65.26
	Days Payable	184.15

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.7
	Shareholder Yield %	14.92

Profitability Rank

7/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	92.8
	Operating Margin %	0.15
	Net Margin %	0.8
	FCF Margin %	0.1
	ROE %	0.75
	ROA %	0.54
	ROIC %	0.03
	ROC (Joel Greenblatt) %	35.76
	ROCE %	5.91
	Years of Profitability over Past 10-Year	7

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	498.86
	Forward PE Ratio	11.09
	PE Ratio without NRI	73.52
	Shiller PE Ratio	83.74
	PS Ratio	3.69
	PB Ratio	4.25
	Price-to-Tangible-Book	4.65
	Price-to-Free-Cash-Flow	418.2
	Price-to-Operating-Cash-Flow	123.83
	EV-to-EBIT	42.09
	EV-to-Forward-EBIT	8.23
	EV-to-EBITDA	31.91
	EV-to-Forward-EBITDA	7.83
	EV-to-Revenue	2.86
	EV-to-Forward-Revenue	2.47
	EV-to-FCF	686.67
	Price-to-Projected-FCF	1.85
	Price-to-Median-PS-Value	0.43
	Price-to-Graham-Number	3.9
	Price-to-Net-Current-Asset-Value	13.91
	Earnings Yield (Greenblatt) %	2.38
	FCF Yield %	0.12

Financials (Next Earnings Date:2025-02-13 Est.)

Annual Quarterly TTM

FRA:ICY's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

Incyte Corp Executives

Details

GF Value: €85.64

FRA:ICY

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with ICY. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	3,734.526
	EPS (TTM) (€)	0.098
	Beta	0.92
	Volatility %	28.2
	14-Day RSI	37
	14-Day ATR (€)	1.405106
	20-Day SMA (€)	68.815
	12-1 Month Momentum %	18.39
	52-Week Range (€)	47.11 - 78.52
	Shares Outstanding (Mil)	192.65

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Incyte Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Incyte Corp Stock Events

Financials Calendars

	Event	Date	Price(€)
No Event Data

Incyte Corp Frequently Asked Questions

What is Incyte Corp(FRA:ICY)'s stock price today?

The current price of FRA:ICY is €64.00. The 52 week high of FRA:ICY is €78.52 and 52 week low is €47.11.

When is next earnings date of Incyte Corp(FRA:ICY)?

The next earnings date of Incyte Corp(FRA:ICY) is 2025-02-13 Est..

Does Incyte Corp(FRA:ICY) pay dividends? If so, how much?

Incyte Corp(FRA:ICY) does not pay dividend.

Press Release

	Subject	Date
No Press Release

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.